Opinion|Videos|April 15, 2024
Myths Surrounding Liquid Biopsy and ctDNA Testing for MRD
Pashtoon Murtaza Kasi, MD, MS, emphasizes key aspects of liquid biopsy and ctDNA testing in the MRD treatment landscape.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA approved sevabertinib in first-line HER2-mutant lung cancer, durvalumab plus tarlatamab boosted survival in ES-SCLC, and more.
The FDA extended the review period for zanzalintinib plus atezolizumab in metastatic colorectal cancer.
Advertisement
Advertisement
Trending on OncLive
1
Pumitamig Plus Elfetabart Drozuntecan Elicits 70% ORR Across Lines of Therapy in SCLC
2
Extended-Interval Tarlatamab Yields Comparable Exposure, Survival to Q2W Dose in Previously Treated SCLC
3
Subcutaneous Tarlatamab Safe, Active Against ES-SCLC Tumors in Phase 1B Trial
4
LCT After Nivolumab/Ipilimumab Induction Fails to Improve Metastatic NSCLC Survival
5